Based on the Cue Biopharma stock forecast from 0 analysts, the average analyst target price for Cue Biopharma is not available over the next 12 months. Cue Biopharma’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cue Biopharma is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Cue Biopharma’s stock price was USD 1.04. Cue Biopharma’s stock price has changed by -11.11% over the past week, -18.11% over the past month and -45.26% over the last year.
No recent analyst target price found for Cue Biopharma
No recent average analyst rating found for Cue Biopharma
Company Overview Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. Read Less
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatmen...Read More
Frequently Asked Questions About Cue Biopharma (CUE) Stock
Stock Target Advisor's fundamental analysis for Cue Biopharma's stock is Bearish.
Unfortunately we do not have enough data on CUE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CUE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CUE's stock to indicate if its overvalued.
The last closing price of CUE's stock was USD 1.04.
The most recent market capitalization for CUE is USD 0.07B.
Unfortunately we do not have enough analyst data on CUE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cue Biopharma's stock.
As per our most recent records Cue Biopharma has 53 Employees.
Cue Biopharma's registered address is 40 Guest Street, Boston, MA, United States, 02135.
You can get more information about it from Cue Biopharma's website at https://www.cuebiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Cue Biopharma (CUE) Stock
Stock Target Advisor's fundamental analysis for Cue Biopharma's stock is Bearish.
Unfortunately we do not have enough data on CUE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CUE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CUE's stock to indicate if its overvalued.
The last closing price of CUE's stock was USD 1.04.
The most recent market capitalization for CUE is USD 0.07B.
Unfortunately we do not have enough analyst data on CUE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cue Biopharma's stock.
As per our most recent records Cue Biopharma has 53 Employees.
Cue Biopharma's registered address is 40 Guest Street, Boston, MA, United States, 02135.
You can get more information about it from Cue Biopharma's website at https://www.cuebiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CUE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
